Abstracts tagged "clinical trial"

Abstract Number: 1208 • ACR Convergence 2020
Utility of Measuring the Immunogenicity to CT-P13 for Subcutaneous Use in Patients with Active Rheumatoid Arthritis: 1-Year Results from a Multicenter, Randomized Controlled Pivotal Trial
Rene Westhovens¹, DaeHyun Yoo², Piotr Wiland³, Marek Zawadzki⁴, Delina Ivanova⁵, Alfredo Berrocal Kasay⁶, Elias Chalouhi⁷, Eva Balázs⁸, SangJoon Lee⁹, SungHyun Kim⁹, JeeHye Suh⁹, ChanKyoung Hwang⁹ and DaeSeok Choi⁹, ¹University Hospitals Leuven, Belgium, Leuven, Belgium, ²Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ³Medical Univeristy, Wroclaw, Poland, ⁴Medical Univeristy, Dpt of Rheumatology , Wroclaw, Wroclaw, Poland, ⁵Diagnostic-Consultative Center Aleksandrovska EOOD, Sofia, Bulgaria, ⁶ABK Reuma SRL, LIMA, Peru, ⁷Clinica Internacional Sede Lima, Lima, Peru, ⁸Dr. Bugyi István Hospital, Szentes, Hungary, ⁹Celltrion, Inc., Incheon, Republic of Korea
Background/Purpose: Novel subcutaneous infliximab (CT-P13 SC) was developed to augment the flexibility in the therapeutic use of infliximab and non-inferiority (NI) of CT-P13 SC versus…
Abstract Number: 1557 • ACR Convergence 2020
Lymphatics as a Biomarker of Joint Physiology: Near-Infrared Imaging of Indocyanine Green Identifies Novel Routes of Lymphatic Drainage from Metacarpophalangeal Joints in Healthy Human Hands
H. Mark Kenney¹, Gregory Dieudonne¹, Ronald Wood¹, Edward Schwarz¹, Christopher Ritchlin² and Homaira Rahimi³, ¹University of Rochester Medical Center, Rochester, ²Department of Medicine, University of Rochester Medical Center, Rochester, NY, ³University of Rochester Medical Center, Rochester, NY
Background/Purpose: In our previous work, we discovered that patients with active hand RA have reduced lymphatic drainage of indocyanine green (ICG) from the web spaces…
Abstract Number: 1990 • ACR Convergence 2020
Janus Kinase (JAK) Inhibition with Baricitinib in Refractory Juvenile Dermatomyositis
Hanna Kim¹, Lylan Bergeron², Samantha Dill², Michelle O'Brien², Laura Vian³, Minal Jain⁴, Manuk Manukyan², Xiaobai Li⁵, Shajia Lu³, Wanxia L. Tsai³, Kalyani Mishra Thakur⁶, Yinghui Shi⁶, Massimo Gadina⁷, April Brundidge², Michelle Millwood², Lisa G. Rider⁸ and Robert Colbert², ¹Juvenile Myositis Pathogenesis and Therapeutics Unit / NIAMS / National Institutes of Health, Bethesda, MD, ²Pediatric Clinical Trials Unit and Office of Clinical Director, NIAMS, NIH, Bethesda, MD, ³Translational Immunology Section, NIAMS, NIH, Bethesda, MD, ⁴Rehabilitation Medicine Department, Physical Therapy Section, Clinical Research Center, NIH, Bethesda, MD, ⁵Biostatistics and Clinical Epidemiology Service, Clinical Center, NIH, Bethesda, MD, ⁶Office of Clinical Director, NIAMS, NIH, Bethesda, MD, ⁷National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, Bethesda, MD, ⁸Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Garrett Park, MD
Background/Purpose: Juvenile dermatomyositis (JDM) is a systemic autoimmune disease with a prominent interferon (IFN) signature. Treatment often requires prolonged high-dose steroids and other immunosuppressive medications.…
Abstract Number: 0209 • ACR Convergence 2020
Upadacitinib as Monotherapy in Patients with Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate: Results at 84 Weeks
Josef Smolen¹, Paul Emery², William Rigby³, Yoshiya Tanaka⁴, Juan Vargas⁵, Nemanja Damjanov⁶, Manish Jain⁷, Yanna Song⁸, Nasser Khan⁹, Jeffrey Enejosa⁹ and Stanley Cohen¹⁰, ¹Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK, Leeds, United Kingdom, ³Dartmouth College, Norwichi, VT, ⁴The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁵Quantum Research, Puerto Varas, Chile, ⁶University of Belgrade Medical School, Belgrade, Serbia, ⁷Great Lakes Clinical Trials, Chicago, IL, ⁸AbbVie Inc., North Chicago,, IL, ⁹AbbVie Inc., North Chicago, IL, ¹⁰Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: In the SELECT-MONOTHERAPY trial, upadacitinib (UPA), an oral JAK inhibitor, demonstrated significantly greater efficacy compared to continuing methotrexate (MTX) when used as monotherapy over…
Abstract Number: 0347 • ACR Convergence 2020
In Two Phase-3 Trials, Guselkumab Reduced Fatigue over 52 Weeks in Patients with Psoriatic Arthritis and Demonstrated Independent Treatment Effects on Fatigue After Adjustment for Clinical Response (ACR20)
Proton Rahman¹, Philip Helliwell², Atul Deodhar³, Alexa Kollmeier⁴, Elizabeth Hsia⁵, Bei Zhou⁶, Xiwu Lin⁶, Chenglong Han⁶ and Philip Mease⁷, ¹Memorial University of Newfoundland, Department of Medicine, St John's, Canada, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Oregon Health & Science University, Portland, OR, ⁴Janssen Research & Development, LLC, La Jolla, CA, ⁵Janssen Research & Development, LLC and University of Pennsylvania Medical Center, Spring House, PA, ⁶Janssen Research & Development, LLC, Spring House, PA, ⁷Seattle Rheumatology Associates, P.L.L.C., Seattle, WA
Background/Purpose: DISCOVER 1 & 2 are phase-3 trials of guselkumab (GUS, an IL-23 inhibitor) in patients with psoriatic arthritis (PsA). In both trials, treatment with…
Abstract Number: 0649 • ACR Convergence 2020
A Multicenter, Open-Label, Efficacy and Safety Study of Pegloticase in Patients with Uncontrolled Gout Who Have Undergone Kidney Transplantation: Early Data Report
Abdul Abdellatif¹, Lin Zhao², Paul Peloso³, Katya Cherny², Brad Marder², John Scandling⁴ and Kenneth Saag⁵, ¹Baylor College of Medicine, Division of Nephrology, Houston, TX, ²Horizon Therapeutics plc, Lake Forest, IL, ³Horizon Therapeutics plc, Gurnee, IL, ⁴Stanford Medicine, Department of Nephrology, Stanford, CA, ⁵University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL
Background/Purpose: Gout’s high prevalence in kidney transplant (KT) recipients has been associated with heavy residual urate burden, decreased urate excretion related to reduced renal function,…
Abstract Number: 0875 • ACR Convergence 2020
Secukinumab Provides Sustained Improvements in Subgroup Analyses of Joint Tenderness and Swelling in Patients with Psoriatic Arthritis: 5‑Year Results from the Phase 3 FUTURE 2 Study
Iain McInnes¹, Hector Chinoy², Darren Asquith³, Abigail White³ and Corine Gaillez⁴, ¹Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²The University of Manchester, Manchester, United Kingdom, ³Novartis Pharmaceuticals UK Ltd., London, United Kingdom, ⁴Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab, a fully human monoclonal antibody that neutralizes interleukin‑17A, has shown long-term efficacy and tolerability in patients with psoriatic arthritis (PsA) in FUTURE 2.…
Abstract Number: 1211 • ACR Convergence 2020
Relationship Between Changes in Lipid Levels and Improvement in Disease Activity Outcomes in Patients with Rheumatoid Arthritis Receiving Upadacitinib Treatment: Pooled Analysis of Data from Two Phase 3 Studies
Christina Charles-Schoeman¹, Jon Giles², Nancy Lane³, Ernest Choy⁴, Heidi Camp⁵, Yanna Song⁶, Samuel Anyanwu⁵ and Iain McInnes⁷, ¹University of California, Los Angeles, Los Angeles, CA, ²Columbia University, New York, NY, ³University of California, Davis, Sacramento, CA, ⁴CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom, ⁵AbbVie Inc., North Chicago, IL, ⁶AbbVie Inc., North Chicago,, IL, ⁷Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Upadacitinib (UPA) is an oral Janus kinase (JAK) inhibitor engineered to have greater selectivity for JAK1 vs JAK2, JAK3, and tyrosine kinase 2, and…
Abstract Number: 1630 • ACR Convergence 2020
Long-term Safety of Tildrakizumab in Patients with Moderate to Severe Plaque Psoriasis: Incidence of Confirmed Major Adverse Cardiovascular Events Through 3 Years (148 Weeks) from Two Phase 3 Trials
Lars Iversen¹, Christopher EM Griffiths², Andrea Peserico³, Ignasi Pau-Charles⁴, Andrew Blauvelt⁵, Diamant Thaçi⁶ and Kristian Reich⁷, ¹Aarhus University Hospital, Aarhus, Denmark, ²The University of Manchester, Manchester, United Kingdom, ³DIMED University of Padua, Padua, Italy, ⁴Almirall R&D, Barcelona, Spain, ⁵Oregon Medical Research Center, Portland, OR, ⁶Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ⁷Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, and Skinflammation®, Hamburg, Germany
Background/Purpose: Tildrakizumab (TIL) is a high-affinity anti–interleukin-23p19 monoclonal antibody that is approved for the treatment of moderate to severe plaque psoriasis. The objective of this…
Abstract Number: 1995 • ACR Convergence 2020
Non-invasive Vagus Nerve Stimulation Improves Signs and Symptoms of Rheumatoid Arthritis: Results of a Pilot Study
Sara Marsal¹, Hector Corominas², Juan Jose De Agustin De Oro³, Carolina Perez Garcia⁴, Maria Lopez Lasanta³, Helena Borrell³, Delia Reina⁵, Raimon Sanmartí⁶, Francisco Javier Narváez⁷, Clara Franco-Jarava⁸, Charles Peterfy⁹, Jose Antonio Narvaez¹⁰, Vivek Sharma¹¹, Konstantinos Alataris¹¹, Mark Genovese¹² and Matthew Baker¹³, ¹Hospital Universitari Vall d'Hebron, Barcelona, Spain, ²Institut Rec. Hospital de la Santa Creu I Sant Pau., Barcelona, Spain, ³Hospital Universitari Vall d’Hebron, Barcelona, Spain, ⁴Hospital Universitari Parc Salut Mar, Barcelona, Spain, ⁵Hospital Moises Broggi, Barcelona, Spain, ⁶Hospital Universitari Clínic de Barcelona, Barcelona, Catalonia, Spain, ⁷Hospital Bellvitge, BARCELONA, Spain, ⁸1Hospital Universitari Vall d’Hebron, Barcelona, Spain, ⁹Spire Sciences, Inc., Boca Raton, FL, ¹⁰Clinica Diagonal, Barcelona, Spain, ¹¹Vorso Corp, Redwood CIty, CA, ¹²Stanford University Medical Center, Palo Alto, CA, ¹³Stanford University, Menlo Park, CA
Background/Purpose: Vagus nerve stimulation (VNS) has been shown to improve rheumatoid arthritis (RA) disease severity in patients with refractory disease (1,2). A multi-center pilot study…
Abstract Number: 0210 • ACR Convergence 2020
Long-term Safety and Efficacy of Sarilumab over 5 Years in Patients with Rheumatoid Arthritis Refractory to Tumor Necrosis Factor Inhibitors
Roy Fleischmann¹, Karina Maslova², Henry Leher³, Amy Praestgaard² and Gerd Burmester⁴, ¹Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX, ²Sanofi, Cambridge, MA, ³Regeneron Pharmaceuticals, Inc, Tarrytown, NY, ⁴Charité University Hospital Berlin, Berlin, Germany
Background/Purpose: Sarilumab is a human IL-6 receptor (IL-6R) inhibitor approved for the treatment of adults with moderate to severely active RA. In the TARGET study…
Abstract Number: 0348 • ACR Convergence 2020
Biologics History and Sex Are Linked to Golimumab Discontinuation in Axial Spondyloarthritis: A Sub-Analysis of the Post-Registration GO-Practice Study
Philippe Bertin¹, Philippe Goupille², Florence Tubach³, Eric Lespessailles⁴, Naoual Harid⁵, Saannya Sequeira⁶, Jean-Marie Fayette⁶, Bruno Fautrel⁷ and Rene-Marc Flipo⁸, ¹Limoges University Hospital, Limoges, France, ²CHU Tours, department of rheumatology, Tours, France, ³Pierre Louis Institute of Epidemiology and Public Health, INSERM 1136, Sorbonne University and Centre of Pharmacoepidemiology, Pitié Salpêtrière Hospital, APHP.Sorbonne University, Paris, Ile-de-France, France, ⁴Regional Hospital and University of Orleans, Orléans, France, ⁵MSD France Puteaux, Puteaux, Ile-de-France, France, ⁶ClinSearch, Malakoff, Ile-de-France, France, ⁷Sorbonne University, INSERM, IPLES; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France, ⁸Lille University Hospital, Lille, France
Background/Purpose: Golimumab (GLM) is the latest anti-TNFα to be indicated for treating rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). The post-registration GO-PRACTICE…
Abstract Number: 0677 • ACR Convergence 2020
A Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled GOut Receiving Pegloticase (MIRROR): 12-Month Results of an Open-Label Study
John Botson¹, Paul Peloso², Katie Obermeyer³, Brian LaMoreaux³, Lin Zhao³, Michael Weinblatt⁴ and Jeff Peterson⁵, ¹Orthopedic Physicians Alaska, Anchorage, AK, ²Horizon Therapeutics plc, Gurnee, IL, ³Horizon Therapeutics plc, Lake Forest, IL, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Western Washington Medical Group Arthritis Clinic, Bothell, WA
Background/Purpose: Consistent, though limited, published data suggests that methotrexate (MTX) improves treatment response in patients treated with pegloticase for uncontrolled (refractory) gout. Recent case series1-3…
Abstract Number: 0877 • ACR Convergence 2020
Improvements in Global Functioning and Health-related Quality of Life and Their Association with Disease Activity and Functional Improvement in Patients with Active Ankylosing Spondylitis Treated with Upadacitinib
Uta Kiltz¹, Joachim Sieper², Atul Deodhar³, Patrick Zueger⁴, In-Ho Song⁴, Naijun Chen⁴ and Désirée van der Heijde⁵, ¹Rheumazentrum Ruhrgebiet, Herne, and Ruhr-University Bochum, Herne, Germany, ²Charité Universitätsmedizin Berlin, Berlin, Germany, ³Oregon Health & Science University, Portland, OR, ⁴AbbVie Inc., North Chicago, IL, ⁵Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Upadacitinib (UPA) has been shown to be effective and well tolerated in patients with active ankylosing spondylitis (AS) [1]. However, improvements in global functioning…
Abstract Number: 1213 • ACR Convergence 2020
Discrepancy Between the Multi-biomarker Disease Activity Score and Clinical Disease Activity Scores in a 2‑Part, Multicenter Study of Repository Corticotropin Injection (Acthar® Gel) for Patients with Persistently Active Rheumatoid Arthritis
Roy Fleischmann¹, Jingyu Liu², Julie Zhu², Oscar Segurado³ and Daniel Furst*⁴, ¹Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX, ²Mallinckrodt Pharmaceuticals, Bedminster, NJ, ³SSI Strategy, San Jose, CA, ⁴Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA, Los Angeles, CA
Background/Purpose: Assessment of disease activity in RA with validated measures, such as the Disease Activity Score with 28 joint count and erythrocyte sedimentation rate (DAS28-ESR)…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].